CUAMC
MCRB icon

China Universal Asset Management Company’s Seres Therapeutics MCRB Stock Holding History

China Universal Asset Management Company’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-164
Closed -$7.82K – 463
2023
Q3 		$7.82K Buy
164
+80
+95% +$6.11K ﹤0.01% 361
2023
Q2 		$8.03K Hold
84
– – ﹤0.01% 333
2023
Q1 		$9.57K Buy
84
+21
+33% +$2.27K ﹤0.01% 297
2022
Q4 		$7.08K Buy
63
+5
+9% +$670 ﹤0.01% 260
2022
Q3 		$7K Buy
+58
New +$5.94K ﹤0.01% 233

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

China Universal Asset Management Company's MCRB Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 164 shares — an estimated $7.82K sold.

China Universal Asset Management Company first reported a position in MCRB in Q3 2022 and held it in 5 quarters. The position peaked at $9.57K in Q1 2023. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • China Universal Asset Management Company reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • China Universal Asset Management Company sold 164 Seres Therapeutics shares in Q4 2023, an estimated $7.82K.
  • China Universal Asset Management Company first reported a position in Seres Therapeutics in Q3 2022 and held it in 5 quarters.
  • China Universal Asset Management Company's Seres Therapeutics position peaked at $9.57K in Q1 2023.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.